MedTrace Logo

Understanding the Impact of Meal Timing on Neurological Health in Adults With Multiple Sclerosis

NCT07475377 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2026-03-18

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if the time an individual eats each day impacts neurological health in people with multiple sclerosis. The main questions the investigators are asking are:

1. Does meal timing affect biomarkers of neuronal health (neurofilament light chain \[NfL\] and BDNF) and inflammation (IL-6, IL-17, TNF-ɑ) in adults with MS.
2. Does meal timing affect expression of circadian clock genes and genes associated with autophagy in adults with MS.

Participants will be instructed to start and stop eating at specific times each day based on their group assignment and their personal schedule. They will respond to prompts sent to them on their smartphone to record the times they start and stop eating each day.

As a secondary goal, the study will also explore the feasibility of including translocator protein (TSPO)-PET imaging of neuroinflammation in future clinical trials of TRE in people with MS. To accomplish this, imaging will be completed in a subset of 8 participants at the beginning and end of the study.

Conditions

Interventions

BEHAVIORAL

Time Restricted Eating

Participants will eat all meals within 8 hours/day and fast for the remaining 16 hours/day.

BEHAVIORAL

Unrestricted eating

Participants will eat all meals over 12 or more hours/day.

Sponsors & Collaborators

  • Paralyzed Veterans of America Research Foundation

    collaborator UNKNOWN

  • University of Alabama at Birmingham

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2027-08-01
Completion
2027-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07475377 on ClinicalTrials.gov